References
- Honkanen RE. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett. 1993;330(3):283–286.
- Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol. 1989;26(2):147–162.
- Efferth T, Rauh R, Kahl S, et al. Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol. 2005;69(5):811–818.
- Karras DJ, Farrell SE, Harrigan RA, et al. Poisoning from “Spanish fly” (cantharidin). Am J Emerg Med. 1996;14(5):478–483.
- Lin CL, Chen CM, Lin CL, et al. Norcantharidin induces mitochondrial-dependent apoptosis through Mcl-1 inhibition in human prostate cancer cells. Biochim Biophys Acta Mol Cell Res. 2017;1864(10):1867–1876.
- Chen F, Wang S, Wei Y, et al. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone. Biomed Pharmacother. 2018;103:1092–1100.
- Jin D, Wu Y, Shao C, et al. Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway. Oncol Rep. 2018;40(2):609–620.
- Jiang S, Li M, Hu Y, et al. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma. Carbohydr Polym. 2018;197:194–203.
- Lu S, Gao Y, Huang X, et al. Cantharidin exerts anti-hepatocellular carcinoma by miR-214 modulating macrophage polarization. Int J Biol Sci. 2014;10(4):415–425.
- Gao Y, Li W, Liu R, et al. Norcantharidin inhibits IL-6-induced epithelial-mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells. Oncol Rep. 2017;38(2):1224–1232.
- Shen HB, Huo ZJ, Bai YJ, et al. Protective effect of norcantharidin on collagen-induced arthritis rats. Chin J Integr Med. 2018;24(4):278–283.
- Ahn CH, Hong KO, Jin B, et al. Contribution of p38 MAPK pathway to norcantharidin-induced programmed cell death in human oral squamous cell carcinoma. Int J Mol Sci. 2019;20(14):pii: E3487.
- Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204–3209.
- Wang Q, Du F, Qian ZM, et al. Lipopolysaccharide induces a significant increase in expression of iron regulatory hormone hepcidin in the cortex and substantia nigra in rat brain. Endocrinology. 2008;149(8):3920–3925.
- Qian ZM, Ke Y. Hepcidin and its therapeutic potential in neurodegenerative disorders. Med Res Rev. 2020;40(2):633–653.
- Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117(3):285–297.
- Ganz T. Anemia of inflammation. N Engl J Med. 2019;381(12):1148–1157.
- Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50.
- Liu MC, Liu L, Wang XR, et al. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo. Int J Nanomedicine. 2016;11:1395–1412.
- Qian ZM, Chang YZ, Zhu L, et al. Development and iron-dependent expression of hephaestin in different brain regions of rats. J Cell Biochem. 2007;102(5):1225–1233.
- Qian ZM, Xiao DS, Ke Y, et al. Increased nitric oxide is one of the causes of changes of iron metabolism in strenuously exercised rats. Am J Physiol. 2001;280(3):R739–R743.
- Qian ZM, Xiao DS, Tang PL, et al. Increased expression of transferrin receptor on membrane of erythroblasts in strenuously exercised rats. J Appl Physiol. 1999;87(2):523–529.
- Jiang DH, Ke Y, Cheng YZ, et al. Distribution of ferroportin1 protein in different regions of developing rat brain. Dev Neurosci. 2002;24(2-3):94–98.
- Chang YZ, Ke Y, Du JR, et al. Increased divalent metal transporter 1 expression might be associated with the neurotoxicity of L-DOPA. Mol Pharmacol. 2006;69:968–974.
- Chen Y, Qian ZM, Du J, et al. Iron loading inhibits ferroportin1 expression in PC12 cells. Neurochem Int. 2005;47:507–513.
- Li L, Xiong ZY, Qian ZM, et al. Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice. Neurobiol Dis. 2014;66:74–82.
- Du F, Qian ZM, Zhu L, et al. Purity, cell viability, expression of GFAP and bystin in astrocytes cultured by different procedures. J Cell Biochem. 2010;109(1):30–37.
- Du F, Zhu L, Qian ZM, et al. Hyperthermic preconditioning protects astrocytes from ischemia/reperfusion injury by up-regulation of HIF-1 alpha expression and binding activity. Biochim Biophys Acta. 2010;1802(11):1048–1053.
- Lu LN, Qian ZM, Wu KC, et al. Expression of iron transporters and pathological hallmarks of Parkinson’s and Alzheimer’s diseases in the brain of young, adult, and aged rats. Mol Neurobiol. 2017;54:5213–5224.
- Ke Y, Ming Qian Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2003;2(4):246–253.
- Ke Y, Qian ZM. Brain iron metabolism: neurobiology and neurochemistry. Prog Neurobiol. 2007;83(3):149–173.
- Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 2006;26:323–342.
- Gutteridge JM, Halliwell B, Treffry A, et al. Effect of ferritin-containing fractions with different iron loading on lipid peroxidation. Biochem J. 1983;209(2):557–560.
- Lawson D M, Treffry A, Artymiuk PJ, et al. Identification of the ferroxidase centre in ferritin. FEBS Lett. 1989;254(1-2):207–210.
- Alkhateeb AA, Connor JR. Nuclear ferritin: a new role for ferritin in cell biology. Biochim Biophys Acta. 2010;1800(8):793–797.
- Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996;1275(3):161–203.
- Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99(10):3505–3516.
- Knovich MA, Storey JA, Coffman LG, et al. Ferritin for the clinician. Blood Rev. 2009;23(3):95–104.
- Galy B, Ferring-Appel D, Kaden S, et al. Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum. Cell Metab. 2008;7(1):79–85.
- Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142(1):24–38.
- Qian ZM, He X, Liang T, et al. Lipopolysaccharides upregulate hepcidin in neuron via microglia and the IL-6/STAT3 signaling pathway. Mol Neurobiol. 2014;50(3):811–820.
- Drakesmith H, Nemeth E, Ganz T. Ironing out ferroportin. Cell Metab. 2015;22(5):777–787.
- Klausner RD, Rouault TA. A double life: cytosolic aconitase as a regulatory RNA binding protein. Mol Biol Cell. 1993;4(1):1–5.
- Hentze MW, Kühn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A. 1996;93(16):8175–8182.
- Qian ZM, Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Rev. 1998;27(3):257–267.
- Du F, Qian C, Qian ZM, et al. Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP-protein kinase A pathway. Glia. 2011;59(6):936–945.
- Du F, Qian ZM, Luo Q, et al. Hepcidin suppresses brain iron accumulation by downregulating iron transport proteins in iron-overloaded rats. Mol Neurobiol. 2015;52(1):101–114.
- Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096–1101.
- Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr. 2008;28:197–213.
- Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093.
- Brasse-Lagnel C, Karim Z, Letteron P, et al. Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. Gastroenterology. 2011;140(4):1261–1271.e1.
- Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015;15(8):500–510.
- Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037–1044.
- Zhang XP, Luo LL, Liu YQ, et al. Norcantharidin combined with diamminedichloroplatinum inhibits tumor growth and cancerometastasis of hepatic carcinoma in murine. J Cancer Res Ther. 2018;14(Supplement):S1035–S1040.
- Mei L, Sang W, Cui K, et al. Norcantharidin inhibits proliferation and promotes apoptosis via c-Met/Akt/mTOR pathway in human osteosarcoma cells. Cancer Sci. 2019;110(2):582–595.
- Wang Y, Yu L, Ding J, et al. Iron metabolism in cancer. Int J Mol Sci. 2018;20(1):pii: E95.
- Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13(5):342–355.
- Hann HW, Stahlhut MW, Blumberg BS. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res. 1988;48(15):4168–4170.
- Beguin Y, Aapro M, Ludwig H, et al. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis – a critical review. Crit Rev Oncol Hematol. 2014;89(1):1–15.
- Shoja Z, Chenari M, Jafarpour A, et al. Role of iron in cancer development by viruses. Rev Med Virol. 2019;29(4):e2045.
- Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023.
- Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615–624.
- Theurl I, Mattle V, Seifert M, et al. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood. 2006;107(10):4142–4148.
- Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009;113(21):5277–5286.
- Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–1443.
- van Santen S, van Dongen-Lases EC, de Vegt F, et al. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2011;63(12):3672–3680.